Endocrine Abstracts

We have identified a signature that predicts response to androgen deprivation therapy in localized prostate cancer, and are now using this signature as a stratification variable on biomarker-driven clinical trials. Following up on the Stand-Up-To-Cancer sequencing findings we design a large umbrella trial which will personalize therapy based on actionable genomic alterations in metastatic castration-resistant prostate cancer.DOI: 10.1530/endoabs.42.IL12<...